Nemaura Medical: Rises as co submits marketing application for glucose monitor

Nemaura Medical

07/07/2020 16:20

** Shares of wearable medical device maker  NMRD.O  rise 6%
to $8.62 after co files marketing application for its
non-invasive and flexible continuous glucose monitor, sugarBEAT 
    ** Says application is under the U.S. Food and Drug
Administration's review for approval of sugarBEAT as a Class III
medical device  urn:newsml:reuters.com:*:nBw2YJyl5a
    ** Class III medical devices are devices that have a high
risk to the patient/user; these devices usually sustain or
support life, are implanted, or present potential unreasonable
risk of illness or injury
    ** Co also plans to launch proBEAT, a device designed to
prompt choices to help users control glucose levels, in the U.S.
later this year 
    ** Stock has more than doubled in value this year

 (Reporting by Sittrarasu S in Bengaluru)
 ((sittrarasu.s@thomsonreuters.com))